Pfizer gets positive opinion from EMA committee for Vizimpro to treat NSCLC with EGFR-activating mutations

Source :: PharmaBiz. February 4, 2019
Publication Year :: 2019
Abstract: Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro (dacomitinib) 45 mg, as monotherapy, [...]

Subjects :: United States. Food and Drug Administration
Pfizer Inc.
Pharmaceutical industry
Epidermal growth factors
Non-small cell lung cancer -- Genetic aspects -- Drug therapy
Cancer metastasis -- Genetic aspects -- Drug therapy
Cancer
Lung cancer
Marketing
Small cell lung cancer
Pharmaceuticals and cosmetics industries
European Union
European Union. European Commission
Vizimpro (Medication)

Tools